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Summary
Shiga and the Shiga-like toxins are related protein
toxins produced by Shigella dysenteriae and certain
strains of Escherichia coli. These toxins are com-
posed of two non-covalently attached, modular parts:
the A moiety (StxA) containing the enzymatically
active A1 fragment, and the non-toxic, pentameric
binding moiety (StxB). Stx binds speciﬁcally to the
glycosphingolipid globotriaosylceramide (Gb3) at the
surface of target cells and is then internalized by
endocytosis. Subsequently, in toxin-sensitive cells,
the Stx/Gb3 complex is transported in a retrograde
manner via the Golgi apparatus to the endoplasmic
reticulum, where the enzymatically active part of Stx
is translocated to the cytosol, enabling it to irrevers-
ibly inhibit protein synthesis via modiﬁcation of ribo-
somal 28S RNA. Whereas Gb3 shows a relatively
restricted expression in normal human tissues, it has
been reported to be highly expressed in many types
of cancers. This review gives a brief introduction to
Stx and its intracellular transport. Furthermore, after
a description of Gb3 and the methods that are cur-
rently used to detect its cellular expression, we
provide an updated overview of the published reports
on Gb3 overexpression in human cancers. Finally, we
discuss the possibility of utilizing Stx or StxB coupled
to therapeutic compounds or contrast agents in tar-
geted cancer therapy and imaging.
Introduction
Shiga toxins, their intracellular transport and
involvement in human disease
The Shiga toxins comprise a family of related protein
toxins secreted by certain types of bacteria. Shiga toxin
(Stx) is produced by Shigella dysenteriae, whereas the
Shiga-like toxins, Stx1 and Stx2, with a few known iso-
forms, are secreted by speciﬁc strains of Escherichia coli
named Shiga-toxin-producing E. coli (STEC). Stx1 is vir-
tually identical to Stx, differing in only one amino acid
residue, whereas the Stx2 isoforms share less sequence
similarity with Stx (~60%) and are immunologically dis-
tinct. In spite of the differences in their amino acid
sequence, all the Stx isoforms share the same overall
toxin structure and mechanism of action, and unless oth-
erwise speciﬁed, for the remainder of this review the sin-
gular term ‘Stx’ will refer to the family of Shiga toxins in
general (for recent reviews on Stx see Sandvig et al.,
2009; Johannes and Römer, 2010).
Gastrointestinal infection with STEC serotypes
might be followed by the life-threatening complication
haemolytic uremic syndrome (HUS), which is deﬁned
by haemolytic anaemia, thrombocytopenia and acute
renal failure (Palermo et al., 2009). HUS predominantly
affects young children, and although the mechanism
is not entirely resolved, the disease involves Stx-
induced damage to kidney cells. The STEC serotypes
associated with HUS produce isoforms of Stx1 or Stx2, or
a combination of these, and the most severe disease
outcome is associated with Stx2 (Boerlin et al., 1999). It
should be noted that, unlike STEC, S. dysenteriae
bacteria invade host cells, and only S. dysenteriae
serotype 1 expresses Stx (for a recent review about dis-
eases caused by S. dysenteriae see Schroeder and Hilbi,
2008).
The Shiga toxins are composed of an enzymatically
active A moiety that is non-covalently attached to a pen-
tameric binding moiety (Fig. 1A–C). The whole natural
toxin is commonly referred to as the ‘holotoxin’. The B
moiety binds speciﬁcally to the sugar domain of the gly-
cosphingolipid globotriaosylceramide (Gb3) (Fig. 1D) in
the plasma membrane of target cells and mediates uptake
and intracellular transport of the toxin (Sandvig et al.,
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endocytic pathway seems to be involved in Stx entry, as
both clathrin-dependent and clathrin-independent toxin
uptake has been identiﬁed in different cell types (Sandvig
et al., 1989; Khine and Lingwood, 1994; Schapiro et al.,
1998; Nichols et al., 2001; Lauvrak et al., 2004; Saint-Pol
et al., 2004; Torgersen et al., 2005; Römer et al., 2007).
The exact contribution of each pathway to toxin uptake is
difficult to determine, as inhibition of one pathway might
lead to upregulation of another (Damke et al., 1995).
Notably, Stx seems to have the ability to stimulate its own
uptake (Torgersen et al., 2005; Lauvrak et al., 2006), and
recently, the toxin was reported to induce tubule formation
(Römer et al., 2007). To which extent tubule-induction
contributes to toxin uptake is unresolved and has been
suggested to be minor (Hansen et al., 2009).
The sorting of Stx into the retrograde transport pathway
from early endosomes to the Golgi apparatus is a highly
regulated process (for recent reviews, see Johannes and
Popoff, 2008; Sandvig et al., 2009; Torgersen et al.,
2010). An overview of components reported to be
involved in this process is shown in Fig. 2. These include,
for instance, SNARE proteins, Rabs, kinases, sorting
nexins, scaffold proteins and cytoskeletal elements.
During intracellular transport, primarily in the endosomes,
the Stx A moiety is cleaved by furin into the A1 and A2
fragments (Fig. 1B) (Garred et al., 1995). The enzymati-
cally active A1 fragment remains bound to the A2 fragment
via a disulﬁde bond during the transport from the Golgi
apparatus to the endoplasmic reticulum (ER), and is
released upon exposure to the reducing conditions in
the ER. The A1 fragment is then translocated into the
cytosol, possibly via the Sec61 complex involved in
ER-associated degradation of misfolded proteins (Yu and
Haslam, 2005). The A1 fragment is able to escape ubiq-
uitination and cytosolic degradation, due to the virtual
absence of lysine residues, and its N-glycosidase activity
irreversibly modiﬁes the ribosomal 28S RNA, leading to
inhibition of protein synthesis. Although this may by itself
lead to cell death, Stx has also been shown to induce
apoptosis via induction of ribotoxic- and ER stress signals
(Smith et al., 2003; Lee et al., 2008), or even via signal
transduction induced by Gb3-ligation (Mangeney et al.,
1993; Taga et al., 1997; Tetaud et al., 2003; Kovbasnjuk
et al., 2005). The mechanism(s) whereby Stx kills cells
still needs further clariﬁcation and seems at least in some
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Fig. 1. The structure of Shiga toxin and its receptor globotriaosylceramide (Gb3).
A. Side view of the 70 kDa holotoxin (PDB protein data bank 1DM0).
B. Schematic presentation of Shiga toxin.
C. Top view of the doughnut-shaped B moiety composed of ﬁve identical 7.7 kDa subunits.
D. Chemical structure of Gb3. The sphingosine backbone (indicated in blue) has a relatively invariable chain length of 18 C-atoms, whereas
the fatty acyl chain (indicated in pink) occurs with both variable lengths and degrees of saturation, here shown as C16:0.
The structures in (A) and (C) were prepared by PDB ProteinWorkshop 3.6 (Moreland et al., 2005), whereas the structure in (D) was prepared
at LIPID MAPS, the Nature Lipidomics Gateway.
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in most cell types, retrograde transport of the toxin to the
ER is a prerequisite for Stx toxicity.
The Shiga toxin receptor, Gb3
The receptor for Shiga toxin in human cells is Gb3. The
glycosphingolipids (GSLs) are a subtype of glycolipids
that are synthesized by the addition of sugar molecules to
a ceramide backbone. The metabolic pathways of GSLs
branch at the point of lactosylceramide (Gal-b1→4Glc-
b1→Cer) into the lacto-, ganglio-, and globo-series (Hako-
mori, 2008). The globoseries of GSLs are unique in
having an a1→4Gal structure at the internal core, result-
ing in an unusual conformational structure distinct from
that of the other series. Gb3 is the ﬁrst product in the
globoseries of GSLs, and is synthesized by the addition of
galactose to lactosylceramide in a reaction catalysed by
Gb3 synthase (a-1,4-galactosyltransferase). For the
molecular structure of Gb3 see Fig. 1D.
Binding of Shiga toxin to Gb3
Binding of Shiga toxin to Gb3 is complex (Peter and
Lingwood,2000;Pinaet al.,2007;Lingwoodet al.,2010b),
and although much has been learned, the Stx–Gb3 inter-
action is far from being completely understood. Crystallo-
graphic studies have indicated that in the context of the
StxB pentamer, each of the ﬁve B-chains has three poten-
tial Gb3 binding sites (Ling et al., 1998), so that at least
in theory, one Stx molecule can simultaneously bind up to
15 Gb3s. Mutational analysis of the Gb3 binding sites in
StxB indicates that at least two of the sites are required for
StxB to be able to bind to Gb3, whereas optimal binding
involves all three binding sites (Soltyk et al., 2002). Fur-
thermore, other studies have indicated that optimal inter-
action between Stx and Gb3 requires a mixture of Gb3
species with different fatty acid chain lengths in their cera-
mide backbone moieties (Pellizzari et al., 1992) combined
with an optimal organization of Gb3 species (Nyholm
et al., 1996), as well as a favourable surrounding lipid
environment in the plasma membrane itself (Arab and
Fig. 2. The intracellular transport pathway of
Shiga toxin. Upon binding to the receptor
Gb3, Shiga toxin is taken in by both
clathrin-dependent and clathrin-independent
pathways, and the toxin–receptor complex is
transported in a retrograde manner from early
endosomes (EE) to the trans-Golgi network
(TGN), the Golgi apparatus and further to
the endoplasmic reticulum (ER). The
enzymatically active A1 fragment is then
translocated into the cytosol where its
N-glycosidase activity irreversibly modiﬁes the
ribosomal 28S RNA, which leads to inhibition
of protein synthesis. Components reported to
be involved in Stx transport are indicated at
each step along the pathway (for references
see Johannes and Popoff, 2008; Sandvig
et al., 2009; Johannes and Römer, 2010;
Starr et al., 2010; Torgersen et al., 2010).
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cation of differences in such factors in vivo, a recent study
reported that due to differential membrane Gb3 organiza-
tion in paediatric versus adult renal glomeruli, Stx binds
stronger to the former (Khan et al., 2009). These ﬁndings
may at least in part explain why STEC-induced HUS is
mainly a paediatric disease.
Differences in the fatty acid chain lengths in the ceram-
ide backbone of Gb3 may alter not only the binding char-
acteristicsofGb3toStx,butalsotheintracellularroutingof
the Gb3/Stx complex. Whereas the sphingosine part of the
ceramide backbone in general appears with a constant
numberof18carbonatoms,thenumberofcarbonatomsin
thefattyacidpartvaries,normallyappearingwithinarange
of 16–24 carbon atoms (C16-C24). There are large cell
type-dependent differences in the species composition of
Gb3 (Raa et al., 2009). In general, however, the most
abundant Gb3 species contains C24, whereas the second
most abundant species contains C22, C18 or C16. Gb3
species with short fatty acid chain lengths (C16 or C18)
have been associated with enhanced retrograde transport
of Stx (Arab and Lingwood, 1998; Raa et al., 2009). So far
there is little information available regarding the species
composition of Gb3 in different tissues.
Methods to detect the Stx receptor Gb3 in cells
and tissues
To evaluate the possibilities of using Stx for imaging
or therapy, one needs to investigate the distribution of
Gb3, and the ability of Gb3 to bind Stx in human cells
and tissues. Different methods have been used for this
purpose, and we therefore provide a brief overview of
those that are most commonly used. Advantages and
disadvantages of these methods are summarized in
Table 1.
Mass spectrometry. Due to recent development within
the ﬁeld of mass spectrometry (MS), the total amount of
Gb3 and the relative content of different Gb3 species in
tissue or cell extracts can now be routinely analysed by
MS. Using high-resolution MS, the analysis may be per-
formed with direct injection of the extracts into the MS
(so-called ‘shot-gun analysis’), i.e. without any chromato-
graphic separation of the samples. The MS analysis also
offers the possibility to obtain information about the total
cellular/tissue lipidome, including the content of other
GSLs, which may give additional important information
about the samples (Raa et al., 2009). We anticipate that
direct MS will play an increasing role in analysis of Gb3 in
the future, but so far most studies have used the more
traditional methods described below.
TLC with orcinol staining or overlay assays. Analysis
of lipid extracts from cells or tissues may be performed
by various chromatographic methods combined with
different types of detection. In practice, chromatogra-
phic analysis of Gb3 is today mainly performed by thin
layer chromatography (TLC) (for reviews see Lingwood
et al., 2010a; Müthing and Distler, 2010). Usually high-
performance TLC (HPTLC) plates are used. Glycolipids
can be visualized by staining carbohydrates with a mixture
of orcinol and sulfuric acid. Information about the identity
and approximate quantity of the bands can be obtained
by comparing the mobility of the band of interest with
a reference, or a set of known glycolipid standards.
Table 1. Advantages and disadvantages of analysing Gb3 by different methods. Examples of published articles where the given technique has
been applied are indicated for each method.
Method Advantages Disadvantages
Mass spectrometry (Müthing and Distler,
2010; Raa et al., 2009)
Identiﬁcation and quantiﬁcation of all Expensive equipment.
Gb3 species. Special knowledge needed.
Very sensitive. Sample must be homogenized and extracted
before analysis.
TLC with orcinol or overlay assays
(Lingwood et al., 2010a; Müthing and
Distler, 2010)
Rapid visualization of several samples.
Do not need expensive equipment.
Relationship between signal intensity and
amount of Gb3 present may be complicated
to interpret when using overlay assays.
Precise species composition not obtained.
Sample must be homogenized and extracted
before analysis.
Fluorescence microscopy/
Immunohistochemistry (Salhia et al.,
2002; Falguières et al., 2008)
Direct visualization of cells. Not possible to obtain reliable quantitative
data of total Gb3 content or the species
composition.
Discriminate between tumour cells and
surrounding tissue.
Flow cytometry (LaCasse et al., 1999;
Tetaud et al., 2003)
Measure distribution of cellular Gb3
expression in a sample.
Possible to estimate the surface level of
Gb3 of non-permeabilized cells.
Not possible to obtain reliable quantitative
data of total Gb3 content or the species
composition.
Expensive equipment.
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bindingofStxoranti-Gb3antibodiestotheGb3specieson
the TLC plate, the plate can be overlaid with Stx, a Stx
derivativeorananti-Gb3antibody,followedbyoverlaywith
a secondary antibody conjugated to a detection moiety for
visualization of the bound molecules. Thus, the TLC
overlay methods are used to indicate the total cellular
levels of Gb3 in the cells/tissue sample. Based on the
differential motility of Gb3 species with, e.g. long or short
fatty acid chain lengths in their ceramide backbone, one
can also obtain indications on the relative expression of
different Gb3 species, which can be further identiﬁed by
MS.The MS identiﬁcation is important, since a single band
on a HPTLC plate is likely to contain different species of
Gb3 (Arab and Lingwood, 1998; Lingwood et al., 2010b).
Fluorescence microscopy/immunohistochemistry of cryo-
sections. These methods are based on visualization of
cellular Gb3 by use of Stx/StxB or anti-Gb3 antibodies
followed by secondary antibodies conjugated to ﬂuores-
cent molecules or enzymes, to allow for detection. Alter-
natively, Stx/StxB or the anti-Gb3 antibodies may be
directly coupled to ﬂuorescent/enzymatic moieties. These
methods give an indication of the in situ total cellular level
of Gb3 if the cells are permeabilized before staining
(which is normally the case), or in situ surface levels of
Gb3 if staining is performed at 4°C on non-permeabilized
preparations. Importantly, in the case of a tumour sample,
one can obtain information on the origin of the Gb3-
expressing cells, i.e. if they are the cancer cells and/or
cells from the surrounding tissue. This is in contrast to MS
and chromatographic methods, which only aim at mea-
suring the total levels of Gb3 in the sample.
Flow cytometry. By use of ﬂow cytometry one can obtain
information on single-cell expression levels of Gb3 in a
large number of cells (normally  10 000 cells are analy-
sed), and thereby obtain information on the distribution of
cellular Gb3 expression levels in the sample. Similarly to
the method mentioned above (ﬂuorescence microscopy/
immunohistochemistry of cryosections), this method is
based on staining of cellular Gb3 by use of Stx/StxB or
anti-Gb3 antibodies followed by ﬂuorescently labelled
secondary antibodies, or alternatively the use of directly
coupled Stx/StxB or anti-Gb3 antibodies. Surface levels
of Gb3 can be determined if staining is performed at
4°C on non-permeabilized cell preparations. The ori-
gin of the Gb3-expressing cells can be assessed by
immunoﬂuorescence-based counterstaining with antibod-
ies towards known cell markers.
Function and expression of Gb3 in humans
Apart from its suggested involvement in negative selec-
tion of tonsillar B cells during affinity maturation (Taga
et al., 1997), the normal function of Gb3 in humans is
unknown. Although not fully characterized, Gb3 appears
to show a relatively restricted expression in normal human
tissues, being mostly found in kidney epithelium and
endothelium (Lingwood, 1994; Khan et al., 2009), in
microvascular endothelial cells in intestinal lamina propria
(Miyamoto et al., 2006; Schuller et al., 2007), in platelets
(Cooling et al., 1998), and in subsets of germinal centre B
lymphocytes (Murray et al., 1985; Gregory et al., 1988;
Mangeney et al., 1991).Alow level of Gb3 expression has
been reported in monocytes (van Setten et al., 1996), and
in monocyte-derived macrophages and dendritic cells
(Falguières et al., 2001). Recent reports indicate that Gb3
is also expressed by intestinal pericryptal myoﬁbroblasts
(Schuller et al., 2007), neurons (Obata et al., 2008) and
endothelial cells in the central nervous system (Johans-
son et al., 2006; Obata et al., 2008), and the possible
implications of this needs to be further clariﬁed. For
example, since primary cultures of human cerebral capil-
lary and microvascular endothelial cells are found to be
largely resistant to Stx (Arab et al., 1998; Ramegowda
et al., 1999; Hughes et al., 2002), it remains to be deter-
mined to what extent Gb3 is expressed at the cell surface
of human brain endothelial cells, and whether Stx is toxic
to these cells in vivo. It should be kept in mind that with
regard to the sensitivity of cells to the toxic action of Stx,
cell surface expression of Gb3 is not always sufficient
(Sandvig et al., 1992; Jacewicz et al., 1994), since in
general the retrograde transport step to the Golgi and ER
is required for Stx toxicity. Moreover, as pointed out
above, the expression of different species of Gb3 may
alter the binding and intracellular routing of Stx.
Expression of Gb3 in human cancers
Aberrant glycosylation appears to be a universal feature
in carcinogenesis, and may alter cell signalling, growth,
adherence and motility (Hakomori, 1989; 1996; Hakomori
and Zhang, 1997). Remarkably, essentially all experimen-
tal and human cancers are found to exhibit alterations in
GSL composition and metabolism (Hakomori and Zhang,
1997), and several tumour-associated antigens have
been found to be GSLs. These include GSLs of the lacto-,
ganglio- and globo-series (Hakomori, 1989; Hakomori
and Zhang, 1997). Interestingly, Gb3 was identiﬁed as a
ﬁbrosarcoma-associated antigen in rats (Ito et al., 1984).
Moreover, the antigen deﬁned by a rat monoclonal anti-
body (referred to as 38.13) directed to a Burkitt’s lym-
phoma cell line was identiﬁed as Gb3 (Nudelman et al.,
1983), and was found to be highly accumulated in a
number of Burkitt’s lymphoma cell lines, as well as in 4 out
of 8 primary Burkitt-like B cell lymphomas (Wiels et al.,
1981) (and see Table 2). Later, Gb3 was found to be
expressed in a large proportion of several other types of B
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1996; 1999). Using another approach, analysing the
overall GSL expression pattern in lipid extracts from
primary human testicular cancer tissues compared with
normal testicular tissue, a marked accumulation of Gb3
was found to be the most conspicuous and consistent
change in testicular tumour extracts (Ohyama et al., 1990;
1992). It should be noted that the patient sample size was
relatively low in these studies, especially for the normal
samples (only four normal tissue samples in each study;
see Table 2). The cancer type for which the highest
number of patients has been analysed for Gb3 expression
is colorectal carcinoma. Here, three separate studies,
which include 141 patients in total, all show that Gb3
expression is signiﬁcantly elevated in the tumours relative
to normal or benign colonic tissue (Kovbasnjuk et al.,
2005; Falguières et al., 2008; Distler et al., 2009). For
other cancer types, the patient sample sizes have in
general been too small to test for statistical signiﬁcance.
However, as shown in Table 2, a clear tendency towards
enhanced Gb3 expression in tumour tissues compared
with the corresponding normal tissue has been observed
in cancers of the ovary (Farkas-Himsley et al., 1995; Arab
et al., 1997), breast (LaCasse et al., 1999; Johansson
et al., 2009) and pancreas (Distler et al., 2009), as well as
in gliomas (Arab et al., 1999; Johansson et al., 2006),
malignant meningiomas (Salhia et al., 2002) and acute
non-lymphocytic leukaemia (Cooling et al., 2003).
For several cancer types, the overexpression of Gb3
reported in patient tumour samples is reﬂected in cultured
cell lines from the same cancer type. For example, in one
study, 13 out of 18 breast cancer cell lines examined
(72%) were found to express Gb3 at their cell surface
(LaCasse et al., 1999), ﬁtting with the ﬁndings by the
same authors that 8 out of 10 primary breast cancer
tumours (80%) expressed Gb3 (LaCasse et al., 1999).
Moreover, a recent study reported Gb3 expression in 17
out of 25 (68%) breast cancers (Johansson et al., 2009).
In another study, 23 out of 23 testicular embryonal carci-
noma cell lines tested showed high expression of Gb3
(Wenk et al., 1994), in agreement with ﬁndings by others
that testicular cancers in general overexpress Gb3
(Ohyama et al., 1990; 1992), and in particular, that the
Gb3 level in 3 out of 3 testicular embryonal carcinomas
and 4 out of 4 testicular embryonal carcinomas plus ter-
atomas was found to be strongly elevated compared with
that in normal testicular tissue (Ohyama et al., 1990).
Interestingly, in several cancer types, not only the cancer
cells themselves are found to overexpress Gb3, but also
the tumour vasculature (Arab et al., 1997; 1999; Salhia
et al., 2002; Johansson et al., 2006; 2009). Moreover, in
some ovarian and breast carcinoma patient samples only
the tumour vasculature, but not the cancer cells, was
found to express Gb3 (Arab et al., 1999; Johansson et al.,
2009), and in studies of gliomas and malignant meningio-
mas, Gb3 was predominantly found in the tumour vascu-
lature (Salhia et al., 2002; Johansson et al., 2006). From
these results, it is tempting to speculate that the cancer
cells secrete factors that induce Gb3 expression in the
tumour vasculature, or alternatively that a host response
towards the tumours may result in such factors being
released to the tumour vasculature. Notably, several
cytokines have been shown to induce Gb3 expression in
endothelial cells (van de Kar et al., 1992; van Setten
et al., 1997; Lingwood, 1999).
Given the relative restricted expression of Gb3 in
human tissues, the above-mentioned reports on Gb3
expression in human cancers raise the possibility that Stx
or Stx derivatives, which speciﬁcally bind to Gb3, may be
used for targeted therapy and imaging of tumours and
tumour vasculature. The feasibility of such a medical
application depends on several factors, among others to
what degree Gb3 is expressed at the cell surface of
various types of normal cells, and to what degree and how
Stx and Stx derivatives are bound to, taken up and trans-
ported inside normal and malignant cells. These and other
aspects related to imaging and targeted cancer therapy of
Gb3-expressing cancers are discussed below.
Use of Stx for targeted imaging and therapy
of cancer
Imaging using labelled StxB
Cancers with overexpression of Gb3 are possible to
image by injecting non-toxic StxB labelled with some type
of imaging agent (Janssen et al., 2006; Viel et al., 2008);
it is not necessary to use the intact toxin for this purpose.
The imaging modalities most useful for targeted imaging
are PET (positron emission tomography), SPECT (single
photon emission-computed tomography) and optical/
ﬂuorescence based techniques due to their high sensitiv-
ity (Weissleder and Pittet, 2008). The positron emitters
most commonly used for PET are 18F and 11C (half-lives of
110 and 20 min respectively), whereas the gamma emitter
99mTc (half-life of 6 h) is by far the most used isotope for
SPECT. These three imaging techniques all have some
advantages and disadvantages. Using the combination of
PET with the X-ray based modality CT (Computed Tomog-
raphy), PET contributes with an extreme sensitivity of the
imaged lesion (10-11-10-12 M of the probe (Phelps, 2000)
in a tissue volume of approximately 1 cm3), whereas CT
gives a nice anatomical picture clearly visualizing where
the lesion is located. A disadvantage with PET is the very
short half-lives of the positron emitters, which therefore
need to be produced by a cyclotron nearby the imaging
centre. Although SPECT in general is 10–100 times
less sensitive than PET, it has the advantage that the
gamma emitter 99mTc is readily available at most hospitals.
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h
a
v
e
t
h
e
r
e
f
o
r
e
n
o
t
e
v
a
l
u
a
t
e
d
w
h
e
t
h
e
r
f
o
l
l
i
c
l
e
c
e
n
t
r
e
l
y
m
p
h
o
m
a
c
e
l
l
s
e
x
p
r
e
s
s
e
n
h
a
n
c
e
d
l
e
v
e
l
s
o
f
G
b
3
c
o
m
p
a
r
e
d
w
i
t
h
n
o
r
m
a
l
f
o
l
l
i
c
l
e
c
e
n
t
r
e
c
e
l
l
s
.
1
4
W
i
t
h
o
r
w
i
t
h
o
u
t
c
h
r
o
n
i
c
l
y
m
p
h
o
c
y
t
i
c
l
e
u
k
a
e
m
i
a
.
1
5
M
a
l
i
g
n
a
n
t
l
y
m
p
h
o
m
a
s
c
l
a
s
s
i
ﬁ
e
d
a
s
c
e
n
t
r
o
b
l
a
s
t
i
c
/
c
e
n
t
r
o
c
y
t
i
c
.
1
6
A
u
t
h
o
r
s
s
t
a
t
e
a
n
d
s
h
o
w
s
o
m
e
e
x
a
m
p
l
e
s
t
h
a
t
l
y
m
p
h
o
m
a
c
e
n
t
r
o
c
y
t
e
s
a
n
d
c
e
n
t
r
o
b
l
a
s
t
s
g
e
n
e
r
a
l
l
y
r
e
a
c
t
e
d
m
o
r
e
s
t
r
o
n
g
l
y
w
i
t
h
t
h
e
a
n
t
i
-
G
b
3
a
n
t
i
b
o
d
y
t
h
a
n
c
e
l
l
s
i
n
n
o
r
m
a
l
g
e
r
m
i
n
a
l
c
e
n
t
r
e
s
.
1
7
S
t
a
i
n
i
n
g
o
f
4
–
5
m
m
c
r
y
o
s
e
c
t
i
o
n
s
w
i
t
h
a
n
t
i
-
G
b
3
a
n
t
i
b
o
d
y
(
c
l
o
n
e
3
8
.
1
3
)
a
n
d
d
e
t
e
c
t
i
o
n
u
s
i
n
g
a
n
a
v
i
d
i
n
-
b
i
o
t
i
n
p
e
r
o
x
i
d
a
s
e
c
o
m
p
l
e
x
i
m
m
u
n
o
p
e
r
o
x
i
d
a
s
e
t
e
c
h
n
i
q
u
e
.
C
r
y
o
s
e
c
t
i
o
n
s
w
e
r
e
ﬁ
x
e
d
i
n
a
c
e
t
o
n
e
,
w
h
i
c
h
a
l
s
o
p
e
r
m
e
a
b
i
l
i
z
e
s
c
e
l
l
s
,
i
.
e
.
t
o
t
a
l
i
n
s
i
t
u
G
b
3
l
e
v
e
l
s
w
e
r
e
a
s
s
e
s
s
e
d
.
1
8
S
t
a
i
n
i
n
g
w
i
t
h
m
o
n
o
c
l
o
n
a
l
r
a
t
I
g
M
a
n
t
i
-
G
b
3
a
n
t
i
b
o
d
y
(
c
l
o
n
e
3
8
.
1
3
)
a
n
d
ﬂ
u
o
r
e
s
c
e
i
n
-
c
o
n
j
u
g
a
t
e
d
a
n
t
i
-
r
a
t
I
g
G
o
n
l
i
v
i
n
g
l
y
m
p
h
o
c
y
t
e
s
a
t
4
°
C
,
i
.
e
.
c
e
l
l
s
u
r
f
a
c
e
l
e
v
e
l
s
o
f
G
b
3
w
e
r
e
a
n
a
l
y
s
e
d
.
1
9
S
a
m
p
l
e
s
f
r
o
m
c
y
s
t
s
/
b
e
n
i
g
n
t
u
m
o
u
r
s
w
e
r
e
o
m
i
t
t
e
d
f
r
o
m
t
h
e
t
a
b
l
e
,
s
i
n
c
e
t
h
e
c
y
s
t
s
s
h
o
w
e
d
i
n
c
r
e
a
s
e
d
l
e
v
e
l
s
o
f
G
b
3
e
x
p
r
e
s
s
i
o
n
c
o
m
p
a
r
e
d
w
i
t
h
n
o
r
m
a
l
o
v
a
r
i
e
s
.
S
a
m
p
l
e
s
f
r
o
m
p
a
t
i
e
n
t
s
w
i
t
h
c
y
s
t
s
/
b
e
n
i
g
n
c
a
n
c
e
r
s
a
r
e
o
n
l
y
i
n
c
l
u
d
e
d
i
n
t
h
e
t
a
b
l
e
i
f
t
h
e
c
y
s
t
s
/
b
e
n
i
g
n
t
u
m
o
u
r
s
d
o
n
o
t
s
h
o
w
e
l
e
v
a
t
e
d
l
e
v
e
l
s
o
f
G
b
3
c
o
m
p
a
r
e
d
w
i
t
h
t
h
e
c
o
r
r
e
s
p
o
n
d
i
n
g
n
o
r
m
a
l
t
i
s
s
u
e
.
T
h
e
r
e
a
s
o
n
i
s
t
o
m
a
k
e
t
h
e
t
a
b
l
e
s
h
o
r
t
e
r
a
n
d
e
a
s
i
e
r
t
o
f
o
l
l
o
w
.
2
0
A
u
t
h
o
r
s
s
t
a
t
e
t
h
a
t
i
n
8
o
u
t
o
f
1
0
o
v
a
r
i
a
n
c
a
n
c
e
r
c
a
s
e
s
,
a
s
i
g
n
i
ﬁ
c
a
n
t
i
n
c
r
e
a
s
e
i
n
G
b
3
e
x
p
r
e
s
s
i
o
n
w
a
s
o
b
s
e
r
v
e
d
.
H
o
w
e
v
e
r
,
a
f
t
e
r
a
c
l
o
s
e
r
i
n
s
p
e
c
t
i
o
n
o
f
t
h
e
d
a
t
a
,
a
n
d
a
f
t
e
r
d
i
v
i
d
i
n
g
t
h
e
b
a
n
d
s
i
n
t
o
n
o
t
d
e
t
e
c
t
a
b
l
e
(
n
o
b
a
n
d
v
i
s
i
b
l
e
o
n
t
h
e
S
t
x
1
T
L
C
o
v
e
r
l
a
y
)
,
w
e
a
k
(
m
u
c
h
w
e
a
k
e
r
t
h
a
n
0
.
5
n
m
o
l
o
f
t
h
e
s
t
a
n
d
a
r
d
)
,
i
n
t
e
r
m
e
d
i
a
t
e
(
c
o
m
p
a
r
a
b
l
e
w
i
t
h
0
.
5
n
m
o
l
o
f
t
h
e
s
t
a
n
d
a
r
d
)
,
a
n
d
s
t
r
o
n
g
(
m
u
c
h
s
t
r
o
n
g
e
r
t
h
a
n
0
.
5
n
m
o
l
o
f
t
h
e
s
t
a
n
d
a
r
d
)
G
b
3
e
x
p
r
e
s
s
i
o
n
,
o
u
r
e
s
t
i
m
a
t
e
s
a
r
e
a
s
f
o
l
l
o
w
s
f
o
r
n
o
r
m
a
l
o
v
a
r
i
e
s
:
n
o
t
d
e
t
e
c
t
a
b
l
e
:
2
/
5
,
w
e
a
k
:
2
/
5
,
i
n
t
e
r
m
e
d
i
a
t
e
:
1
/
5
,
f
o
r
o
v
a
r
i
a
n
c
a
n
c
e
r
s
:
n
o
t
d
e
t
e
c
t
a
b
l
e
:
2
/
1
0
,
w
e
a
k
:
3
/
1
0
,
i
n
t
e
r
m
e
d
i
a
t
e
:
4
/
5
,
s
t
r
o
n
g
:
1
/
1
0
.
T
h
u
s
,
5
o
u
t
o
f
1
0
o
v
a
r
i
a
n
c
a
n
c
e
r
s
e
x
p
r
e
s
s
i
n
t
e
r
m
e
d
i
a
t
e
-
t
o
-
h
i
g
h
l
e
v
e
l
s
o
f
G
b
3
,
w
h
e
r
e
a
s
1
/
5
n
o
r
m
a
l
o
v
a
r
i
e
s
e
x
p
r
e
s
s
e
s
i
n
t
e
r
m
e
d
i
a
t
e
l
e
v
e
l
s
o
f
G
b
3
.
T
h
u
s
,
w
e
p
r
o
p
o
s
e
t
h
a
t
a
r
e
a
s
o
n
a
b
l
e
e
s
t
i
m
a
t
e
f
r
o
m
t
h
e
s
e
d
a
t
a
i
s
t
h
a
t
5
o
u
t
o
f
t
h
e
1
0
o
v
a
r
i
a
n
c
a
n
c
e
r
s
e
x
p
r
e
s
s
e
d
m
o
r
e
G
b
3
t
h
a
n
t
h
e
a
v
e
r
a
g
e
f
r
o
m
t
h
e
n
o
r
m
a
l
o
v
a
r
i
e
s
.
A
l
t
e
r
n
a
t
i
v
e
l
y
,
a
n
o
t
h
e
r
w
a
y
t
o
i
n
t
e
r
p
r
e
t
t
h
e
d
a
t
a
:
8
/
1
0
(
8
0
%
)
o
v
a
r
i
a
n
c
a
n
c
e
r
s
e
x
p
r
e
s
s
e
d
G
b
3
,
w
h
e
r
e
a
s
3
/
5
(
6
0
%
)
n
o
r
m
a
l
o
v
a
r
i
e
s
e
x
p
r
e
s
s
e
d
G
b
3
.
2
1
O
u
r
o
w
n
c
a
l
c
u
l
a
t
i
o
n
b
a
s
e
d
o
n
n
u
m
b
e
r
s
i
n
T
a
b
l
e
1
i
n
t
h
e
p
u
b
l
i
c
a
t
i
o
n
.
S
a
m
p
l
e
s
s
h
o
w
i
n
g

s
i
x
f
o
l
d
h
i
g
h
e
r
G
b
3
l
e
v
e
l
s
t
h
a
n
t
h
e
a
v
e
r
a
g
e
G
b
3
l
e
v
e
l
i
n
n
o
r
m
a
l
o
v
a
r
i
e
s
a
r
e
r
e
g
a
r
d
e
d
a
s
s
a
m
p
l
e
s
w
i
t
h
e
n
h
a
n
c
e
d
G
b
3
e
x
p
r
e
s
s
i
o
n
.
2
2
O
u
r
o
w
n
c
a
l
c
u
l
a
t
i
o
n
b
a
s
e
d
o
n
n
u
m
b
e
r
s
i
n
T
a
b
l
e
1
i
n
t
h
e
p
u
b
l
i
c
a
t
i
o
n
.
2
3
B
i
n
d
i
n
g
o
f
S
t
x
B
–
F
I
T
C
t
o
f
r
o
z
e
n
t
u
m
o
u
r
o
r
n
o
r
m
a
l
t
i
s
s
u
e
f
r
o
m
s
e
l
e
c
t
e
d
p
a
t
i
e
n
t
s
g
e
n
e
r
a
l
l
y
c
o
r
r
e
l
a
t
e
d
w
i
t
h
t
h
e
l
e
v
e
l
s
o
f
G
b
3
e
x
t
r
a
c
t
e
d
f
r
o
m
t
h
e
t
i
s
s
u
e
(
a
s
m
e
a
s
u
r
e
d
b
y
S
t
x
1
T
L
C
o
v
e
r
l
a
y
)
.
L
i
t
t
l
e
o
r
n
o
s
t
a
i
n
i
n
g
w
i
t
h
S
t
x
B
–
F
I
T
C
w
a
s
s
e
e
n
i
n
s
e
c
t
i
o
n
s
o
f
n
o
r
m
a
l
o
v
a
r
y
.
E
x
t
e
n
s
i
v
e
b
i
n
d
i
n
g
o
f
S
t
x
B
–
F
I
T
C
t
o
t
h
e
l
u
m
e
n
o
f
b
l
o
o
d
v
e
s
s
e
l
s
t
h
a
t
v
a
s
c
u
l
a
r
i
z
e
t
h
e
t
u
m
o
u
r
w
a
s
a
l
s
o
o
b
s
e
r
v
e
d
,
e
v
e
n
i
n
G
b
3
-
n
e
g
a
t
i
v
e
t
u
m
o
u
r
s
.
2
4
‘
N
o
G
b
3
’
(
0
–
1
5
%
S
t
x
B
–
F
I
T
C
-
p
o
s
i
t
i
v
e
c
e
l
l
s
)
:
2
/
1
0
.
‘
W
e
a
k
G
b
3
’
(
1
5
–
4
0
%
S
t
x
B
–
F
I
T
C
-
p
o
s
i
t
i
v
e
c
e
l
l
s
)
:
3
/
1
0
.
‘
I
n
t
e
r
m
e
d
i
a
t
e
G
b
3
’
(
4
1
–
7
0
%
S
t
x
B
–
F
I
T
C
-
p
o
s
i
t
i
v
e
c
e
l
l
s
)
:
4
/
1
0
.
‘
S
t
r
o
n
g
G
b
3
’
(
7
1
–
1
0
0
%
S
t
x
B
–
F
I
T
C
-
p
o
s
i
t
i
v
e
c
e
l
l
s
)
:
1
/
1
0
.
T
h
a
t
i
s
,
5
/
1
0
b
r
e
a
s
t
c
a
n
c
e
r
s
w
e
r
e
i
n
t
e
r
m
e
d
i
a
t
e
t
o
s
t
r
o
n
g
l
y
p
o
s
i
t
i
v
e
f
o
r
c
e
l
l
s
u
r
f
a
c
e
G
b
3
.
2
5
G
b
3
e
x
p
r
e
s
s
i
o
n
w
a
s
f
o
u
n
d
i
n
s
o
m
e
t
u
m
o
u
r
c
e
l
l
s
i
n
1
7
o
f
t
h
e
2
5
b
r
e
a
s
t
c
a
n
c
e
r
s
p
e
c
i
m
e
n
s
.
I
t
w
a
s
n
o
t
f
u
r
t
h
e
r
s
t
a
t
e
d
h
o
w
e
x
t
e
n
s
i
v
e
t
h
e
G
b
3
e
x
p
r
e
s
s
i
o
n
w
a
s
i
n
t
h
e
s
e
1
7
s
p
e
c
i
m
e
n
s
,
a
n
d
a
l
s
o
n
o
t
s
t
a
t
e
d
i
f
t
h
e
r
e
w
e
r
e
d
i
f
f
e
r
e
n
c
e
s
w
i
t
h
i
n
t
h
e
s
e
1
7
s
p
e
c
i
m
e
n
s
,
e
.
g
.
i
f
s
o
m
e
s
h
o
w
e
d
h
i
g
h
e
r
e
x
p
r
e
s
s
i
o
n
t
h
a
n
o
t
h
e
r
s
.
G
b
3
e
x
p
r
e
s
s
i
o
n
w
a
s
d
e
t
e
c
t
e
d
i
n
v
a
s
c
u
l
a
r
e
n
d
o
t
h
e
l
i
a
l
c
e
l
l
s
i
n
a
l
l
2
5
t
u
m
o
u
r
s
p
e
c
i
m
e
n
s
.
2
6
U
s
i
n
g
a
n
t
i
-
G
b
3
a
n
t
i
b
o
d
i
e
s
o
n
c
r
y
o
s
e
c
t
i
o
n
s
.
A
r
a
t
m
o
n
o
c
l
o
n
a
l
I
g
M
a
n
t
i
b
o
d
y
f
r
o
m
I
m
m
u
n
o
t
e
c
h
,
M
a
r
s
e
i
l
l
e
,
w
a
s
u
s
e
d
(
t
h
i
s
i
s
m
o
s
t
l
i
k
e
l
y
t
h
e
3
8
.
1
3
c
l
o
n
e
)
.
C
r
y
o
s
t
a
t
s
p
e
c
i
m
e
n
s
w
e
r
e
ﬁ
x
e
d
a
n
d
p
e
r
m
e
a
b
i
l
i
z
e
d
w
i
t
h
a
c
e
t
o
n
e
,
i
.
e
.
t
o
t
a
l
i
n
s
i
t
u
l
e
v
e
l
s
o
f
G
b
3
w
e
r
e
a
n
a
l
y
s
e
d
.
2
7
5
o
u
t
o
f
6
s
e
m
i
n
o
m
a
s
,
3
o
u
t
o
f
3
e
m
b
r
y
o
n
a
l
c
a
r
c
i
n
o
m
a
s
,
a
n
d
4
o
u
t
o
f
4
e
m
b
r
y
o
n
a
l
c
a
r
c
i
n
o
m
a
s
+
t
e
r
a
t
o
m
a
,
s
h
o
w
e
d
s
t
r
o
n
g
l
y
e
l
e
v
a
t
e
d
G
b
3
l
e
v
e
l
s
.
2
8
F
o
r
s
e
l
e
c
t
e
d
s
a
m
p
l
e
s
,
e
l
e
v
a
t
i
o
n
o
f
G
b
3
e
x
p
r
e
s
s
i
o
n
w
a
s
c
o
n
ﬁ
r
m
e
d
w
i
t
h
a
n
t
i
-
G
b
3
a
n
t
i
b
o
d
y
(
1
A
4
=
c
l
o
n
e
3
8
.
1
3
)
T
L
C
o
v
e
r
l
a
y
.
T
h
e
i
d
e
n
t
i
t
y
o
f
G
b
3
w
a
s
a
l
s
o
c
o
n
ﬁ
r
m
e
d
b
y
p
u
r
i
ﬁ
c
a
t
i
o
n
a
n
d
s
u
b
s
e
q
u
e
n
t
d
e
g
r
a
d
a
t
i
o
n
w
i
t
h
a
-
g
a
l
a
c
t
o
s
i
d
a
s
e
.
2
9
1
2
o
u
t
o
f
1
2
s
e
m
i
n
o
m
a
s
,
a
n
d
0
o
u
t
o
f
2
t
e
s
t
i
c
u
l
a
r
m
a
l
i
g
n
a
n
t
l
y
m
p
h
o
m
a
s
s
h
o
w
e
d
s
t
r
o
n
g
l
y
e
l
e
v
a
t
e
d
G
b
3
l
e
v
e
l
s
.
3
0
G
b
3
w
a
s
d
e
t
e
c
t
e
d
o
n
l
y
i
n
a
f
r
a
c
t
i
o
n
o
f
t
u
m
o
u
r
c
e
l
l
s
i
n
a
n
y
o
n
e
s
e
c
t
i
o
n
.
I
n
n
o
r
m
a
l
b
r
a
i
n
s
,
G
b
3
w
a
s
e
x
p
r
e
s
s
e
d
o
n
l
y
i
n
e
n
d
o
t
h
e
l
i
a
l
c
e
l
l
s
.
I
n
4
/
7
t
u
m
o
u
r
s
e
c
t
i
o
n
s
,
t
h
e
e
n
d
o
t
h
e
l
i
u
m
s
t
a
i
n
e
d
p
o
s
i
t
i
v
e
f
o
r
G
b
3
.
3
1
E
x
t
e
n
s
i
v
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possible to extend the time between injection and imaging
to allow more of the free, unbound probe to be excreted
before imaging. This is very important as a main challenge
of targeted imaging is to reduce the signal from tissue
nearby the lesion such that a good signal-to-noise ratio is
obtained. A rapid excretion of the targeting compound not
bound to the lesion (normally less than 2–3% of the
injected dose is retained at the molecular target) is there-
fore important.
It has been shown that it is possible to detect tumours
in the digestive tract of mice (spontaneous tumorigenesis
models were used) after force-feeding the animals with a
single dose of 300–500 mg ﬂuorescence-labelled StxB
using confocal laser endoscopy, or after retro-orbital injec-
tion of 18F-labelled StxB followed by PET imaging 1–2 h
after injection (Janssen et al., 2006) (the precise dose of
18F-labelled StxB was not stated, but was referred to as
a ‘tracer’ dose). Later the same group reported imaging
of tumours subcutaneously implanted in mice (specimen
from human colon cancer) from 5 h to 9 days after giving
50 mg of ﬂuorescence-labelled StxB by oral, intraperito-
neal or intravenous administration (Viel et al., 2008).
The best signal-to-noise ratio was obtained 2–4 days
after intravenous administration. The images presented
in these two studies showed considerable background
signals from various tissues, such that it could have been
a challenge to detect the tumours if not knowing where to
look for them. It should be noted that a biodistribution
study performed in mice using autoradiography (cryosec-
tions of 40 mm) following intravenous injection of 125I-
labelled Stx1 or Stx2 showed considerable amounts of
radioactivity in several tissues. Thus, Stx1 was found, e.g.
in lungs, kidney cortex and bone marrow; whereas Stx2
did not target the lung, but accumulated in kidneys to a
greater extent than Stx1 (Rutjes et al., 2002).
Ideally targeted imaging in the clinic should be per-
formed using intravenous injection (simple administration,
low dose and a homogenous delivery), and the targeting
substance should be as small as possible to allow for
rapid renal excretion of free, unbound substance. The
StxB pentamer has a ‘doughnut’ shaped structure with a
central pore (Fig. 1C), and thus its hydrodynamic size is
larger than expected for a globular protein with a mass of
38.5 kDa. StxB may therefore be too large to obtain a
rapid renal excretion of the free, unbound substance, and
future studies are needed to learn if StxB clearance is fast
enough to be useful for PET or SPECT imaging or if
smaller Gb3-binding substances have to be investigated.
The longer half-life for 99mTc than the isotopes used for
PET imaging makes it more likely that StxB can be suc-
cessfully used with SPECT than with PET. Both these
imaging techniques have the advantage that deep-seated
lesions (the whole body) can be imaged.
One advantage with optical and ﬂuorescent probes is
that it is possible to extend the time between injection of
the substance and imaging, thus allowing more time for
clearance of the free, unbound probe. The time needed
for clearance/excretion of a substance normally increases
with the size of the animal. Although it is difficult to predict
elimination half-lives across species, an indication of this
species difference is that a substance cleared by glom-
erular ﬁltration is excreted approximately 5 times faster in
rats than in humans (Lin, 1998). Optical/ﬂuorescence-
based imaging techniques have the disadvantage that it is
not possible to image deep into tissues; most of these
techniques allow imaging of only 1–2 cm into the tissue.
These techniques are therefore most useful for imaging of
surface areas, including those that can be reached by
detecting probes in body cavities or during surgery. Thus,
intravenous injection of StxB labelled with a ﬂuorescent
probe seems to be an attractive opportunity for targeted
imaging of cancers with overexpression of Gb3, which are
close to a surface that can be reached with the detecting
probe. It should be noted that all three imaging techniques
described above should be expected to give similar
images whether the labelled substance is bound to the
cell surface or taken up into the cell; it is the concentration
within a given tissue volume that matters.
Targeted therapy using Stx or StxB
The reported overexpression of Gb3 in many cancers
opens for the possibility of using either the holotoxin (Stx)
or StxB coupled to therapeutic drugs in targeted cancer
therapy. Whereas the ﬁrst option in general requires that
the cancer cells are able to transport the toxin to the ER
and translocate the toxic A1 fragment into the cytosol, for
the second option, the ability of the cancer cells to bind or
take up StxB may be sufficient for a therapeutic effect.
The two options are expected to give different therapeutic
effects as well as different side effects, and this is dis-
cussed below.
The simplest choice for targeted therapy of Gb3 over-
expressing cancers would be to utilize the natural holo-
toxin, the crucial point being whether it can be tolerated by
humans (see discussion below). Stx harbours several
advantageous properties compared with conventional
chemotherapeutic drugs. It kills cells in an extremely
effective manner (theoretically, one toxin molecule is
enough to kill a cell), and thus, Stx could possibly have
therapeutic effects at low doses and with only one or a few
rounds of treatment. The latter has indeed been shown
to be the case in several murine cancer models. Thus,
intratumoral or intraperitoneal injection of Stx1 inhibited
tumour growth in a murine metastatic ﬁbrosarcoma
model (Farkas-Himsley et al., 1995), as well as in mouse
xenograft models of human malignant meningiomas
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with endothelial characteristics (Heath-Engel and Ling-
wood, 2003), human renal carcinoma (Ishitoya et al.,
2004) and human astrocytoma (Arab et al., 1999).
Remarkably, in the two latter cases, complete regression
of the tumours was reported 7–10 days after a single
intratumoral injection of Stx1, and apoptosis was shown to
occur in both tumour cells (Arab et al., 1999; Ishitoya
et al., 2004) and vascular cells (Arab et al., 1999) within
the treated grafts. Moreover, no side effects were reported
in these murine models. In the latter mentioned study, the
mice were followed up for more than 50 days post treat-
ment, during which the animals remained tumour free and
were without apparent side effects (Arab et al., 1999).
Another advantage with Stx compared with conventional
chemotherapeutic drugs is the fact that Stx kills cells by a
distinct mechanism that is independent of most drug-
resistant cancer cell phenotypes. Thus, Stx might be able
to kill cancer cells that would otherwise escape chemo-
therapeutic treatment and lead to a relapse. Intriguingly,
some reports indicate that drug-resistant cancer cells are
in fact hypersensitive to the toxic effect of Stx (Farkas-
Himsley et al., 1995;Arab et al., 1997; 1998; 1999), imply-
ing that Stx may be extremely effective in the treatment of
multidrug-resistant cancers. One could imagine a form of
treatment that combines chemotherapeutic drugs with
very low doses of Stx (the latter to kill drug-resistant
cancer cells).
A major concern with the use of the active Stx in cancer
therapy would be the putative side effects, given that upon
infection with bacteria that produce Stx1/Stx2 (STECs),
life-threatening complications arising from HUS can occur,
in which Stx in most instances in believed to play a crucial
etiological role. Of note, however, serious complications
due to STEC infection are very rare, and occur primarily in
a minor fraction of young children and the elderly. More-
over, puriﬁed Stx is less likely to induce HUS than an
STEC infection, since other virulence factors than Stx
such as adhesins, other toxins and proteases also con-
tribute to STEC-induced disease (Palermo et al., 2009).
Furthermore, not only Stx, but also other bacterial factors
such as lipopolysaccharide and ﬂagellin are believed to
contribute to enhance the damaging effect of Stx via
induction of cytokines that upregulate Gb3 expression in
endothelial cells (Proulx et al., 2001; Tarr et al., 2005;
Palermo et al., 2009). Thus, one would expect Stx-
mediated damage to the endothelium to be more pro-
nounced in the context of an STEC infection than when
highly puriﬁed (lipopolysaccharide-free) Stx is adminis-
tered alone. Moreover, administrating Stx alone allows for
controlled toxin dosage, localization and choice of Stx
isoform. Of note, Stx1 is generally found to be more toxic
to cultured cancer cells than Stx2. Interestingly, however,
STECs that produce Stx2 are much more frequently asso-
ciated with HUS than STECs producing only Stx1 (Boerlin
et al., 1999), indicating that Stx1 may be less toxic in vivo
than Stx2. This was indeed shown to be the case for
juvenile baboons [in which tissue localization and quantity
of Gb3 is similar to humans (Tesh et al., 1994)] develop-
mentally comparable to 3- to 6-year-old humans, as these
animals tolerated four consecutive intravenous injections
with 25 ng kg-1 Stx1, but not Stx2 (Siegler et al., 2003).
Given the observation that Stx-hypersensitive cancer
cells can be killed by as little as 1 pg ml-1 Stx1 in vitro,a
dose of 25 ng kg-1 Stx1 could be clinically efficient. More-
over, adult baboons (and adult humans) are likely to tol-
erate higher doses of Stx1 than juvenile baboons, and
higher doses of Stx can be expected to be tolerated upon
e.g. intratumoral than upon intravenous injection of Stx. In
conclusion, it is conceivable that e.g. Stx1 could be used
in the treatment of non-elderly, adult cancer patients.
However, more studies are required to assess the short-
and long-term effects of Stx in animals and humans.
If adverse reactions should turn out to prohibit the direct
use of active holotoxin in cancer therapy, an alternative for
some cancer types could be to purge the cancer cells ex
vivo. Ex vivo Stx1 treatment has indeed been shown to be
highly efficient in eradicating malignant B cells from lym-
phoma and myeloma patient samples, whereas at the
same time leaving haematopoietic progenitor cells unaf-
fected (LaCasse et al., 1999). This indicates that Stx1
may be used as an ex vivo purging agent to eliminate
malignant cells from autologous stem cell grafts.
As an alternative to using the holotoxin for targeted
cancer therapy, the non-toxic StxB could be used to bring
drugs to the cancers the same way as described above
for bringing imaging modules to cancers. If used thera-
peutically instead of for imaging, there is no need for rapid
excretion of the targeting molecule, and it is probably an
advantage if the substance is circulating for a longer time.
StxB should in principle be useful to bring therapeutic
isotopes, normally alfa or beta emitters (Dahle and
Larsen, 2008; Dancey et al., 2009), or other drugs to
cancers with overexpression of Gb3. Using therapeutic
isotopes it should be sufficient with surface-binding
of isotopes to kill the cells overexpressing Gb3. This
approach would be expected to give different and perhaps
additional side effects than if using the holotoxin, since it
will potentially be toxic to all normal cells that express Gb3
at the cell surface, whereas the holotoxin in general is
toxic only to cells that in addition are able to transport the
toxin in a retrograde manner to the ER and the cytosol.
For example, isotope-coupled StxB, but not the holotoxin,
might kill monocyte-derived macrophages and dendritic
cells, as it has been reported that these cells take up
StxB, but direct it to the degradative pathway instead of to
the Golgi (Falguières et al., 2001). A different approach
would be to conjugate StxB to a drug that has a thera-
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drug to the cytosol. Strategies to avoid the drugs from
killing normal cells include the use of phototoxic com-
pounds or the use of drugs that preferentially kill cancer
cells. In the former case, StxB-mediated targeting of Gb3-
expressing cancer cells is reﬁned with a second level of
speciﬁcity by local illumination of the tumour. The release
of drugs to the cytosol is in general quite a challenge.
Thus, the combined property of StxB both to target Gb3-
expressing cancer cells and to transport drugs to the
cytosol via retrograde transport to the ER is rather unique.
However, in some Gb3-expressing cancer cells, the ret-
rograde transport pathway for StxB is inefficient. Photo-
chemical internalization includes use of substances (e.g.
porphyrins) that are taken up into the endosomal mem-
brane and after light treatment generate free radicals,
which destroy the endosomes (Berg et al., 2007). Thus, in
addition to adding a second level of speciﬁcity in the
targeting of cancers (as mentioned above), linking StxB to
photochemical substances can improve the efficiency of
drug delivery to the cytosol. StxB photosensitizer conju-
gates have indeed been shown to be highly effective in
killing cancer cells in vitro (Tarrago-Trani et al., 2006;
Amessou et al., 2008). StxB coupled to drugs that prefer-
entially kill cancer cells have also been synthesized and
tested on cancer cells in vitro. In one study, the active
principle of the topoisomerase I inhibitor camptothecin 11,
which is used in the treatment of colorectal cancers, was
bound to StxB through a disulﬁde linkage, the idea being
that the drug would be released after retrograde transport
to the reducing environment in the ER (El Alaoui et al.,
2007). This conjugate was indeed shown to be highly
cytotoxic to HT29 colorectal carcinoma cells in vitro (El
Alaoui et al., 2007). The selection of cancer cells would, in
this case, not only be due to the fact that the topoi-
somerase inhibitor preferentially kills cancer cells, but also
that a prodrug was used (due to conjugation to StxB), so
that the active drug would only be released in cells that
are able to transport StxB to the ER.As a general note, as
is the case with the holotoxin, more studies are required to
assess the short and long-term effects of StxB and the
various StxB derivatives in animals and humans.
Concluding remarks and future perspectives
The numerous reports that indicate a selective overex-
pression of Gb3 in various types of human cancers
warrant further research into the potential application of
Stx or StxB derivatives in cancer medicine. Several issues
need to be clariﬁed. First, many of the studies on Gb3
expression in cancer have analysed too few patient
samples to be able to test for statistical signiﬁcance. Thus,
there is a need for studies with larger patient sample sizes.
There is also a general need for better characterization of
the Gb3 expression levels in non-malignant human
tissues. Given the complexity of Stx binding to Gb3, a
future challenge also lies in the accurate detection and
discrimination between different Gb3 species and their
plasma membrane environment in cancer cells versus
non-malignant cells, as well as in the interpretation of such
information. Thus, we also need to learn more about the
implications of Stx binding to different kinds of Gb3s, both
concerning Stx binding and endocytosis, but also concern-
ing the effects on the intracellular trafficking of Stx.
Using StxB coupled to contrast agents, we expect
imaging of Gb3-expressing cancers to be more feasible
with SPECT than with PET, due to the likely relatively slow
renal clearance of StxB. Even more feasible, in theory, is
the use of StxB coupled to optical or ﬂuorescent probes,
although this limits the application to imaging of cancers
that can be reached with the detecting probe, i.e. within
body cavities or during operations. Although StxB is non-
toxic in vitro, the short- and long-term effects of StxB and
its derivatives need to be tested further in animal models.
This is also a critical issue concerning the potential use of
Stx, or StxB coupled to therapeutic agents, in the treat-
ment of cancer patients. The exceptionally potent antican-
cer effect of Stx observed in murine cancer models
justiﬁes further research into clarifying whether Stx or Stx
derivatives can be exploited in the cancer clinic.
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